肿瘤预防与治疗2026，Vol.39Issue(4)：247-255,9.DOI:10.3969/j.issn.1674-0904.2026.04.001
铂耐药卵巢癌免疫治疗:困境、突破与未来方向
Immunotherapy for Platinum-Resistant Ovarian Cancer:Dilemmas,Breakthroughs,and Future Directions
摘要
Abstract
Ovarian cancer is characterized by high incidence and mortality rates.Traditional treatment modalities are mainly surgery combined with platinum-based chemotherapy,but recurrence and platinum resistance rates are high.For pa-tients with advanced-stage disease,the 5-year survival rate is less than 30％,creating an urgent need to explore novel thera-peutic strategies.Immunotherapy has improved the prognosis of patients with various solid tumors and has opened new avenues for the treatment of ovarian cancer.However,most previous studies—in the settings of first-line maintenance,plati-num-sensitive,and platinum-resistant populations—have not yielded positive results.The KEYNOTE-B96 study demonstra-ted,for the first time,that regardless of PD-L1 status,pembrolizumab combined with weekly paclitaxel(with or without bevacizumab)significantly improved progression-free survival and overall survival in patients with platinum-resistant ovarian cancer compared with placebo,with a manageable safety profile.This breakthrough finding is expected to estab-lish this regimen as a new standard treatment for platinum-resistant recurrent ovarian cancer.关键词
卵巢癌/铂耐药/免疫治疗/免疫检查点抑制剂/KEYNOTE-B96 研究Key words
Ovarian cancer/Platinum resistance/Immunotherapy/Immune checkpoint inhibitor/KEYNOTE-B96 study分类
医药卫生引用本文复制引用
张国楠,孔北华,马丁..铂耐药卵巢癌免疫治疗:困境、突破与未来方向[J].肿瘤预防与治疗,2026,39(4):247-255,9.基金项目
This study was supported by grants from University of Electronic Science and Technology of China(No.YXYLCJJ202403008). 电子科技大学医学院临床医学学科发展基金重点课题(编号:YXYLCJJ202403008) （No.YXYLCJJ202403008）
